“Our team combines international expertise with shared standards of quality and ethics.”
Frantisek Sedlak
Chief Medical Officer
While we continue to work with our partners toward licensing and further development of our IP, we are happy to apply our expertise to selected project on a fee for service basis.
We pride ourselves on our collaborative approach, working closely with our partners to understand their specific needs and challenges. This enables us to tailor our solutions, ensuring that our LNP technology not only meets but exceeds expectations. Our goal is to be a trusted partner in the development of next-generation therapeutics, driving innovations that pave the way for new treatments and cures.
Built on academic excellence, flexibility and reliability
Extensive library of pre-clinically tested LNPs
Proprietary high-throughput assembly platform
In-house R&D facilities, access to animal facilities
Flexible collaborations based on your priorities
Main R&D Areas
Design and synthesis of novel lipids and lipidoids
Design and synthesis of novel outer shell modifiers (lipid-polymer conjugates)
Radiolabeled and stable-isotope lipids to support ADME studies
Synthetic process technology transfer to CDMO
Formulation development and optimization using scalable components and processes
Process characterization and optimization
Manufacturing process technical transfer to CDMO
Analytical methods development and transfer, including lipid and nucleic acid-specific analyses
Biophysical characterization including LNP size and size distribution, cargo encapsulation, surface charge and pKa, cryo-electron microscopy
Bioanalytical method development and analyses for LNP components
Pharmacodynamic studies for protein replacement therapeutics
Reporter gene (e.g. luciferase) expression in vivo by luminescent live-imaging
Reporter tissue/cell gene expression ex vivo by flow cytometry, luminescence spectroscopy
Transgene expression by immunohistochemistry/
immunocytochemistry
Safety/tolerability studies
Clinical pathology/histopathology
Immune response characterization (e.g. complement, cytokines/chemokines)
Transgene expression by immunohistochemistry/
immunocytochemistry
Bioanalytical
Nucleic acid therapeutics
LNP components
We focus on successful management of the research program to meet partner objectives:
Reporter gene (e.g. luciferase) expression in vivo by luminescent live-imaging
Reporter tissue/cell gene expression ex vivo by flow cytometry, luminescence spectroscopy
Transgene expression by immunohistochemistry/
immunocytochemistry
Main R&D Areas
Synthetic Chemistry
Design and synthesis of novel lipids and lipidoids
Design and synthesis of novel lipids and lipidoids
Radiolabeled and stable-isotope lipids to support ADME studies
Synthetic process technology transfer to CDMO
Product Formulation and Scale-up
Formulation development and optimization using scalable components and processes
Process characterization and optimization
Manufacturing process technical transfer to CDMO
Analytical and Biophysical Characterization
Analytical methods development and transfer, including lipid and nucleic acid-specific analyses
Biophysical characterization including LNP size and size distribution encapsulation, surface charge and pKa, cryo-electron microscopy
Bioanalytical method development and analyses for LNP components
Preclinical characterization
Pharmacodynamic studies for protein replacement therapeutics
Reporter gene (e.g. luciferase) expression in vivo by luminescent live-imaging
Reporter tissue/cell gene expression ex vivo by flow cytometry, luminescence spectroscopy
Transgene expression by immunohistochemistry/
immunocytochemistry
Safety/tolerability studies
Clinical pathology/histopathology
Immune response characterization (e.g. complement, cytokines/chemokines)
Transgene expression by immunohistochemistry/
immunocytochemistry
Bioanalytical
Nucleic acid therapeutic
LNP components
Research Program Management
We focus on successful management of the research program to meet partner objectives:
Reporter gene (e.g. luciferase) expression in vivo by luminescent live-imaging
Reporter tissue/cell gene expression ex vivo by flow cytometry, luminescence spectroscopy
Transgene expression by immunohistochemistry/
immunocytochemistry
Next-generation lipid nanoparticles for gene delivery.
Billing information
Adalid Sciences, s.r.o.
Podbabska 2582/30
160 00, Praha 6
Czech Republic
Reg. No 21691053
VAT No CZ21691053
